An exploration of the advantages of automated titration testing: low inter‐instrument variability and equivalent accuracy for ABO and non‐ABO antibody titres relative to tube testing

Vox Sanguinis ◽  
2020 ◽  
Vol 115 (4) ◽  
pp. 314-322
Author(s):  
Brian D. Adkins ◽  
Shanna A. Arnold Egloff ◽  
Kayla Fahey‐Ahrndt ◽  
Andrea L. Kjell ◽  
Claudia S. Cohn ◽  
...  
Keyword(s):  
Antibody Titres ◽  
Automated Titration

THE HEXOSAMINE CONTENT OF THE ORBIT IN RELATION TO ANTI-THYROTROPHIN ANTIBODY TITRES IN SERA OF THYROTROPHIN-TREATED RABBITS WITH AND WITHOUT CORTISONE ADMINISTRATION

1962 ◽  
Vol 41 (3) ◽  
pp. 474-480 ◽  
Author(s):  
Otto Wegelius ◽  
E. J. Jokinen
Keyword(s):  
Connective Tissue ◽  
Guinea Pigs ◽  
Antibody Formation ◽  
Direct Proof ◽  
Significant Rise ◽  
Extraocular Muscles ◽  
Concomitant Treatment ◽  
Antibody Titres ◽  
Hexosamine Content ◽  
Synergetic Action

ABSTRACT In all previous investigations on experimental exophthalmos, heterologous thyrotrophic pituitary extracts have been used. These protein hormones stimulate antihormone formation in the test animals. Cortisone has been reported to effectively block antibody formation. In addition, it has been shown to potentiate TSH-induced exophthalmos in guinea-pigs. With rabbits as test animals, the hexosamine content of the orbital tissues was determined and used as an index of exophthalmos development and at the same time the antibody titres in the sera were followed. TSH injections for six weeks led to a highly significant accumulation of hexosamine in the retrobulbar connective tissue and in the extraocular muscles, i. e. an increase of up to 400% as compared with the control animals. At the same time a significant rise in antihormonal titres was detectable in the sera. Concomitant treatment with cortisone brought about an equal or higher accumulation of hexosamine but significantly lower antibody titres. The known opposite peripheral actions of TSH and cortisone can be reconciled with the synergy in producing experimental exophthalmos by attributing the synergetic action of cortisone to the blocking of antihormone formation. If less antihormones are produced, the effect of TSH is enhanced. Our experiments do not provide direct proof for this hypothesis. High hexosamine values in the orbit and low antihormone titres in the serum are, however, concomitant phenomena.

scholarly journals Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?

Infection ◽  
2021 ◽  
Author(s):  
Ali Hamady ◽  
JinJu Lee ◽  
Zuzanna A. Loboda
Keyword(s):  
Cross Reactivity ◽  
Antibody Responses ◽  
The Novel ◽  
Incidence And Mortality ◽  
Antibody Titres ◽  
Human Coronaviruses ◽  
Public Health Strategies ◽  
Antibody Dynamics

Abstract Objectives The coronavirus disease 2019 (COVID-19), caused by the novel betacoronavirus severe acute respiratory syndrome 2 (SARS-CoV-2), was declared a pandemic in March 2020. Due to the continuing surge in incidence and mortality globally, determining whether protective, long-term immunity develops after initial infection or vaccination has become critical. Methods/Results In this narrative review, we evaluate the latest understanding of antibody-mediated immunity to SARS-CoV-2 and to other coronaviruses (SARS-CoV, Middle East respiratory syndrome coronavirus and the four endemic human coronaviruses) in order to predict the consequences of antibody waning on long-term immunity against SARS-CoV-2. We summarise their antibody dynamics, including the potential effects of cross-reactivity and antibody waning on vaccination and other public health strategies. At present, based on our comparison with other coronaviruses we estimate that natural antibody-mediated protection for SARS-CoV-2 is likely to last for 1–2 years and therefore, if vaccine-induced antibodies follow a similar course, booster doses may be required. However, other factors such as memory B- and T-cells and new viral strains will also affect the duration of both natural and vaccine-mediated immunity. Conclusion Overall, antibody titres required for protection are yet to be established and inaccuracies of serological methods may be affecting this. We expect that with standardisation of serological testing and studies with longer follow-up, the implications of antibody waning will become clearer.

scholarly journals Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
James A. Hutchinson ◽  
Katharina Kronenberg ◽  
Paloma Riquelme ◽  
Jürgen J. Wenzel ◽  
Gunther Glehr ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Serum Antibody ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Effector Memory ◽  
Specific Memory ◽  
Immune Mediated ◽  
Antibody Titres ◽  
Pre Treatment ◽  
After Cancer

AbstractTreatment of advanced melanoma with combined PD-1/CTLA-4 blockade commonly causes serious immune-mediated complications. Here, we identify a subset of patients predisposed to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion of effector memory CD4+ T cells (TEM cells). Pre-therapy CD4+ TEM cell expansion occurs primarily during autumn or winter in patients with metastatic disease and high cytomegalovirus (CMV)-specific serum antibody titres. These clinical features implicate metastasis-dependent, compartmentalised CMV reactivation as the cause of CD4+ TEM expansion. Pre-therapy CD4+ TEM expansion predicts hepatitis in CMV-seropositive patients, opening possibilities for avoidance or prevention. 3 of 4 patients with pre-treatment CD4+ TEM expansion who received αPD-1 monotherapy instead of αPD-1/αCTLA-4 therapy remained hepatitis-free. 4 of 4 patients with baseline CD4+ TEM expansion given prophylactic valganciclovir and αPD-1/αCTLA-4 therapy remained hepatitis-free. Our findings exemplify how pathogen exposure can shape clinical reactions after cancer therapy and how this insight leads to therapeutic innovations.

scholarly journals A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Alexander Lind ◽  
Ilaria Marzinotto ◽  
Cristina Brigatti ◽  
Anita Ramelius ◽  
Lorenzo Piemonti ◽  
...  
Keyword(s):  
Antibody Response ◽  
Antigenic Determinant ◽  
Etiological Agent ◽  
Healthy Controls ◽  
Antibody Affinity ◽  
Antibody Titres ◽  
Antibody Levels ◽  
And Control ◽  
Radiobinding Assay

AbstractAn increased incidence of narcolepsy type 1 (NT1) was observed in Scandinavia following the 2009–2010 influenza Pandemrix vaccination. The association between NT1 and HLA-DQB1*06:02:01 supported the view of the vaccine as an etiological agent. A/H1N1 hemagglutinin (HA) is the main antigenic determinant of the host neutralization antibody response. Using two different immunoassays, the Luciferase Immunoprecipitation System (LIPS) and Radiobinding Assay (RBA), we investigated HA antibody levels and affinity in an exploratory and in a confirmatory cohort of Swedish NT1 patients and healthy controls vaccinated with Pandemrix. HA antibodies were increased in NT1 patients compared to controls in the exploratory (LIPS p = 0.0295, RBA p = 0.0369) but not in the confirmatory cohort (LIPS p = 0.55, RBA p = 0.625). HA antibody affinity, assessed by competition with Pandemrix vaccine, was comparable between patients and controls (LIPS: 48 vs. 39 ng/ml, p = 0.81; RBA: 472 vs. 491 ng/ml, p = 0.65). The LIPS assay also detected higher HA antibody titres as associated with HLA-DQB1*06:02:01 (p = 0.02). Our study shows that following Pandemrix vaccination, HA antibodies levels and affinity were comparable NT1 patients and controls and suggests that HA antibodies are unlikely to play a role in NT1 pathogenesis.

scholarly journals Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Mohammad W. Bahar ◽  
Claudine Porta ◽  
Helen Fox ◽  
Andrew J. Macadam ◽  
Elizabeth E. Fry ◽  
...  
Keyword(s):  
Significant Risk ◽  
Next Generation ◽  
Wild Type ◽  
Inactivated Polio Vaccine ◽  
Vaccination Programs ◽  
Virus Like Particles ◽  
Mammalian Expression ◽  
Cryo Electron Microscopy ◽  
Alternative Expression ◽  
Antibody Titres

AbstractGlobal vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk in a polio-free world. Recombinant PV virus-like particles (VLPs), lacking the viral genome, represent safe next-generation vaccines, however their production requires optimisation. Here we present an efficient mammalian expression strategy producing good yields of wild-type PV VLPs for all three serotypes and a thermostabilised variant for PV3. Whilst the wild-type VLPs were predominantly in the non-native C-antigenic form, the thermostabilised PV3 VLPs adopted the native D-antigenic conformation eliciting neutralising antibody titres equivalent to the current IPV and were indistinguishable from natural empty particles by cryo-electron microscopy with a similar stabilising lipidic pocket-factor in the VP1 β-barrel. This factor may not be available in alternative expression systems, which may require synthetic pocket-binding factors. VLPs equivalent to these mammalian expressed thermostabilized particles, represent safer non-infectious vaccine candidates for the post-eradication era.

scholarly journals Antibody responses in buffalos immunized with Clostridium perfringens beta and epsilon toxoids

2001 ◽  
Vol 46 (No. 9–10) ◽  
pp. 241-243 ◽  
Author(s):  
S. Rahman M ◽  
K. Baek B ◽  
T. Hong S ◽  
H. Lee J
Keyword(s):  
Antibody Titre ◽  
Clostridium Perfringens ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Control Group ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Antibody Titres ◽  
Group A ◽  
And Control

The antibody responses to toxoids were measured to investigate whether Clostridium perfringens beta and epsilon toxoids induced protective humoral immune responses in buffalos. Total of 24 buffalos were divided into 4 groups (n = 6), beta toxoid, epsilon toxoid, combination and control groups. These buffalo groups were administered each of the designated toxoids. Immunizations in the beta and epsilon toxoid groups induced strong antibody responses. The neutralizing antibody titres from the beta and epsilon toxoid groups were equally log101.2 on day 21 after inoculation whereas there was no antibody titre detected from the control group. A statistically significant (P < 0.01) increase in antibody titre was observed from day 0 to day 14 and 21 after inoculation. The antibody production did not vary significantly due to day of inoculation and toxoid interactions.

scholarly journals Risk Factors for Kaposi’s Sarcoma–Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda

2019 ◽  
Vol 71 (4) ◽  
pp. 1055-1062 ◽  
Author(s):  
Angela Nalwoga ◽  
Marjorie Nakibuule ◽  
Vickie Marshall ◽  
Wendell Miley ◽  
Nazzarena Labo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Viral Load ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Young Males ◽  
Viral Shedding ◽  
Antibody Titres ◽  
Kaposi's Sarcoma Associated Herpesvirus ◽  
Kaposi’S Sarcoma Associated Herpesvirus ◽  
Ugandan Population

Abstract Background Detectable Kaposi’s sarcoma–associated herpesvirus (KSHV) DNA in blood and increased antibody titres may indicate KSHV reactivation, while the transmission of KSHV occurs via viral shedding in saliva. Methods We investigated the risk factors for KSHV DNA detection by real-time polymerase chain reaction in blood and by viral shedding in saliva, in 878 people aged 3 to 89 years of both sexes in a rural Ugandan population cohort. Helminths were detected using microscopy and the presence of malaria parasitaemia was identified using rapid diagnostic tests. Regression modelling was used for a statistical analysis. Results The KSHV viral load in blood did not correlate with the viral load in saliva, suggesting separate immunological controls within each compartment. The proportions of individuals with a detectable virus in blood were 23% among children aged 3–5 years and 22% among those 6–12 years, thereafter reducing with increasing age. The proportions of individuals with a detectable virus in saliva increased from 30% in children aged 3–5 years to 45% in those aged 6–12 years, and decreased subsequently with increasing age. Overall, 29% of males shed in saliva, compared to 19% of females (P = .008). Conclusions Together, these data suggest that young males may be responsible for much of the onward transmission of KSHV. Individuals with a current malaria infection had higher levels of viral DNA in their blood (P = .031), compared to uninfected individuals. This suggests that malaria may lead to KSHV reactivation, thereby increasing the transmission and pathogenicity of the virus.

scholarly journals A potential krimpsiekte vaccine

2007 ◽  
Vol 74 (4) ◽  
Author(s):  
C.J. Botha ◽  
J.E. Crafford ◽  
V.P. Butler ◽  
M.N. Stojanovic ◽  
L. Labuschagne
Keyword(s):  
South Africa ◽  
Bovine Serum Albumin ◽  
Immunological Response ◽  
The Other ◽  
The Third ◽  
Protein Conjugate ◽  
Bovine Serum Albumin Conjugate ◽  
Small Stock ◽  
Antibody Titres ◽  
Glycoside Poisoning

Krimpsiekte, a chronic form of cardiac glycoside poisoning, is an important plant-induced intoxication of small stock in South Africa. It is caused by cumulative, neurotoxic bufadienolides, such as cotyledoside. A cotyledoside-bovine serum albumin conjugate was synthesized to immunize animals. The efficacy of the cotyledoside-conjugate in inducing an immunological response was ascertained in rabbits (n = 4) and sheep (n = 4) by determining cotyledoside antibody titres with an ELISA using cotyledoside-hen ovalbumin as antigen. The formation of anticotyledoside antibodies was induced in both rabbits and sheep following immunization with the cotyledoside-protein conjugate. Protection provided by the vaccine was demonstrated by challenging sheep (n = 4) with repeated, daily doses of cotyledoside (0.015 mg / kg) administered intravenously, commencing 45 days after the initial vaccination. One control animal died on Day 3 of the challenge period and the other was severely affected after administration of the third cotyledoside dose. The immunized ewes (n = 2) remained clinically unaffected and the challenge was suspended following six daily injections. Vaccination as a means of preventing krimpsiekte seems to be quite feasible and deserves further investigation.

Sign in / Sign up

Export Citation Format

Share Document